{"id":513125,"date":"2021-07-14T16:08:28","date_gmt":"2021-07-14T20:08:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/"},"modified":"2021-07-14T16:08:28","modified_gmt":"2021-07-14T20:08:28","slug":"codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/","title":{"rendered":"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">REDWOOD CITY, Calif., July  14, 2021  (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver<sup>\u00ae<\/sup> platform technology transfer with Novartis Pharma AG (\u201cNovartis\u201d) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver<sup>\u00ae<\/sup> to develop novel performance enzymes for use in the manufacture of pharmaceutical products.<\/p>\n<p align=\"justify\">\u201cWe are pleased to have completed the CodeEvolver<sup>\u00ae<\/sup> installation for Novartis, enabling our long-time customer to leverage Codexis\u2019 proprietary enzyme engineering technology,\u201d said Stefan Lutz, Senior Vice President of Research of Codexis. \u201cCompared to using traditional, non-enzymatic chemistry, CodeEvolver<sup>\u00ae<\/sup>-improved enzymes and processes can reduce capital requirements, and enable higher yielding processes, with reduced energy usage and lower waste generation. This is our third licensing collaboration for a customer to bring CodeEvolver<sup>\u00ae<\/sup> technology in-house, but the first one we have had to implement virtually; I\u2019m extremely proud of how our teams collaborated to ensure a successful and efficient technology transfer, despite the challenges of the pandemic.\u201d<\/p>\n<p>\n        <strong>About Codexis<\/strong>\n      <\/p>\n<p align=\"justify\">Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver<sup>\u00ae<\/sup> platform to discover and develop novel, high performance enzymes and novel biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; the creation of the next generation of life science tools; and as biologic therapeutics and in gene therapy. The Company\u2019s unique enzymes drive improvements such as reduced energy usage, waste generation and capital utilization, higher yields, higher fidelity diagnostics, and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ukxr7k1fWXy_WtDa5uI-TA502ZSZ4j2CkRdJAzueNzmn3n3s-tF3Q6oAD4CSRT4obSvZAZ_8W94YhOpGBLOpng==\" rel=\"nofollow noopener\" target=\"_blank\">www.codexis.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis\u2019 control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis\u2019 dependence on its licensees and collaborators; Codexis\u2019 dependence on a limited number of products and customers and potential adverse effects to Codexis\u2019 business if its customers\u2019 products are not received well in the markets. Additional information about factors that could materially affect actual results can be found in Codexis\u2019 Annual Report on Form 10-K filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 1, 2021, and in Codexis\u2019 Quarterly Report on Form 10-Q filed with the SEC on May 7, 2021, including under the caption \u201cRisk Factors,\u201d and in Codexis\u2019 other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Argot Partners<br \/>Stephanie Marks\/Carrie McKim<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=p6L5WJcW7l9CxdwQhpfIbrSJJDRk5-4FF4J7OYvR3HlX2c8yPM0VbH5PX3bqo7i_yD3X11qAHjTQZmpxInc_Ie71G9TSauG5pP8oP8Q7zGM=\" rel=\"nofollow noopener\" target=\"_blank\">Codexis@argotpartners.com<\/a>\u00a0<br \/>(212) 600-1902<\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ab583305-5787-4e57-a8fe-f4244530a32b\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver\u00ae platform technology transfer with Novartis Pharma AG (\u201cNovartis\u201d) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver\u00ae to develop novel performance enzymes for use in the manufacture of pharmaceutical products. \u201cWe are pleased to have completed the CodeEvolver\u00ae installation for Novartis, enabling our long-time customer to leverage Codexis\u2019 proprietary enzyme engineering technology,\u201d said Stefan Lutz, Senior Vice President of Research of Codexis. \u201cCompared to using traditional, non-enzymatic chemistry, CodeEvolver\u00ae-improved enzymes and processes can reduce capital &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-513125","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver\u00ae platform technology transfer with Novartis Pharma AG (\u201cNovartis\u201d) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver\u00ae to develop novel performance enzymes for use in the manufacture of pharmaceutical products. \u201cWe are pleased to have completed the CodeEvolver\u00ae installation for Novartis, enabling our long-time customer to leverage Codexis\u2019 proprietary enzyme engineering technology,\u201d said Stefan Lutz, Senior Vice President of Research of Codexis. \u201cCompared to using traditional, non-enzymatic chemistry, CodeEvolver\u00ae-improved enzymes and processes can reduce capital &hellip; Continue reading &quot;Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-14T20:08:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader\",\"datePublished\":\"2021-07-14T20:08:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/\"},\"wordCount\":515,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/\",\"name\":\"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=\",\"datePublished\":\"2021-07-14T20:08:28+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/","og_locale":"en_US","og_type":"article","og_title":"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader - Market Newsdesk","og_description":"REDWOOD CITY, Calif., July 14, 2021 (GLOBE NEWSWIRE) &#8212; Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, announced the completion of the CodeEvolver\u00ae platform technology transfer with Novartis Pharma AG (\u201cNovartis\u201d) today. In May 2019, the two companies signed a platform technology transfer and license agreement, under which Novartis has a non-exclusive license to CodeEvolver\u00ae to develop novel performance enzymes for use in the manufacture of pharmaceutical products. \u201cWe are pleased to have completed the CodeEvolver\u00ae installation for Novartis, enabling our long-time customer to leverage Codexis\u2019 proprietary enzyme engineering technology,\u201d said Stefan Lutz, Senior Vice President of Research of Codexis. \u201cCompared to using traditional, non-enzymatic chemistry, CodeEvolver\u00ae-improved enzymes and processes can reduce capital &hellip; Continue reading \"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-14T20:08:28+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader","datePublished":"2021-07-14T20:08:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/"},"wordCount":515,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/","name":"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=","datePublished":"2021-07-14T20:08:28+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4MDU5NSM0Mjk3Njc2IzIwMTY1MzQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/codexis-announces-completion-of-codeevolver-license-technology-transfer-with-global-pharmaceutical-leader\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Codexis Announces Completion of CodeEvolver\u00ae License Technology Transfer with Global Pharmaceutical Leader"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513125","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=513125"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/513125\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=513125"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=513125"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=513125"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}